THMO (ThermoGenesis Holdings) FCF Margin % : -19.18% (As of Mar. 2024)

View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ThermoGenesis Holdings's Free Cash Flow for the three months ended in Mar. 2024 was $-0.53 Mil. ThermoGenesis Holdings's Revenue for the three months ended in Mar. 2024 was $2.74 Mil. Therefore, ThermoGenesis Holdings's FCF Margin % for the quarter that ended in Mar. 2024 was -19.18%.

As of today, ThermoGenesis Holdings's current FCF Yield % is -3,580,900.00%.

The historical rank and industry rank for ThermoGenesis Holdings's FCF Margin % or its related term are showing as below:

THMO' s FCF Margin % Range Over the Past 10 Years
Min: -47.79 Med: 0 Max: 0
Current: -47.79

THMO's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -3.46 vs THMO: -47.79

ThermoGenesis Holdings FCF Margin % Historical Data

The historical data trend for ThermoGenesis Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings FCF Margin % Chart

ThermoGenesis Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-26.38

-147.95

-72.23

-73.29

-57.74

ThermoGenesis Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-53.89	-61.68	-19.64	-92.89	-19.18

Competitive Comparison of ThermoGenesis Holdings's FCF Margin %

For the Medical Devices subindustry, ThermoGenesis Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ThermoGenesis Holdings's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's FCF Margin % falls into.

Save Embed

;

Save Embed

;

ThermoGenesis Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ThermoGenesis Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-5.454	/	9.445
	=	-57.74 %

ThermoGenesis Holdings's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-0.525	/	2.737
	=	-19.18 %

ThermoGenesis Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (OTCPK:THMO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2711 Citrus Road, Rancho Cordova, CA, USA, 95742

Website

https://www.thermogenesis.com

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Executives

Xiaochun Xu	director	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu	director	2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu	director	2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy	director	C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph	director	MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford	director	7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate	director	350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble	officer: Principal Accounting Officer	2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu	director
Boyalife Investment Inc.	10 percent owner	2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545